NTLA

Intellia Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$10.55

Price (1 Year)

$17.56 $8.99

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %4.2 / %30
Non-compliant assets / Total market cap %26.2 / %30
Non-compliant revenue / Total income %36.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing.

Website

Analysis (Turkish): NTLA Hissesi Caiz mi, Helal mi? Intellia Therapeutics, Inc. Katılım Analizi